Novo Nordisk Ramps Up Legal Fight Against Compounded Semaglutide Knockoffs
August 06, 2025
With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect patients from unapproved compounded semaglutide products by targeting pharmacies, telehealth providers, and deceptive marketing practices that compromise safety, mislead consumers, and violate FDA regulations.